427 related articles for article (PubMed ID: 8661389)
1. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
2. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
Junker U; Böhnlein E; Veres G
Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
[TBL] [Abstract][Full Text] [Related]
3. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
5. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.
Robinson D; Elliott JF; Chang LJ
Gene Ther; 1995 Jun; 2(4):269-78. PubMed ID: 7552987
[TBL] [Abstract][Full Text] [Related]
6. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells.
Natarajan V; Radjendirane V; Salzman NP
Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789
[TBL] [Abstract][Full Text] [Related]
7. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS.
Manca F; Fenoglio D; Franchin E; Saverino D; Li Pira G; Buffa F; Bignardi D; Del Pup L; Palù G
Gene Ther; 1997 Nov; 4(11):1216-24. PubMed ID: 9425445
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
9. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1.
Chang HK; Gendelman R; Lisziewicz J; Gallo RC; Ensoli B
Gene Ther; 1994 May; 1(3):208-16. PubMed ID: 7584083
[TBL] [Abstract][Full Text] [Related]
10. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 by a double transdominant fusion gene.
Aguilar-Cordova E; Chinen J; Donehower LA; Harper JW; Rice AP; Butel JS; Belmont JW
Gene Ther; 1995 May; 2(3):181-6. PubMed ID: 7614248
[TBL] [Abstract][Full Text] [Related]
12. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
15. Antitat gene therapy: a candidate for late-stage AIDS patients.
Lisziewicz J; Sun D; Lisziewicz A; Gallo RC
Gene Ther; 1995 May; 2(3):218-22. PubMed ID: 7614253
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.
Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL
Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266
[TBL] [Abstract][Full Text] [Related]
17. Tat and rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells.
Duan L; Oakes JW; Ferraro A; Bagasra O; Pomerantz RJ
Virology; 1994 Mar; 199(2):474-8. PubMed ID: 8122376
[TBL] [Abstract][Full Text] [Related]
18. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication.
Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG
Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme.
Unwalla H; Chakraborti S; Sood V; Gupta N; Banerjea AC
Antiviral Res; 2006 Nov; 72(2):134-44. PubMed ID: 16790281
[TBL] [Abstract][Full Text] [Related]
20. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1.
Yamada O; Yu M; Yee JK; Kraus G; Looney D; Wong-Staal F
Gene Ther; 1994 Jan; 1(1):38-45. PubMed ID: 7584058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
